telmisartan has been researched along with Colitis Gravis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Basuony, M; Eldin, AS; Saber, S | 1 |
Araújo Júnior, RF; Araújo, AA; Fernandes, D; Guerra, GC; Lira, GA; Melo, MN; Silva, AL; Souto, KK | 1 |
2 other study(ies) available for telmisartan and Colitis Gravis
Article | Year |
---|---|
Telmisartan ameliorates dextran sodium sulfate-induced colitis in rats by modulating NF-κB signalling in the context of PPARγ agonistic activity.
Topics: Animals; bcl-2-Associated X Protein; CD36 Antigens; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Heme Oxygenase (Decyclizing); Male; NF-E2-Related Factor 2; Peroxidase; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Telmisartan; Transcription Factor RelA | 2019 |
Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis.
Topics: Animals; Benzimidazoles; Benzoates; Colitis, Ulcerative; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Inflammation; Interleukin-10; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Telmisartan; Tumor Necrosis Factor-alpha | 2015 |